These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Status of and perspectives on psychiatric genomic medicine]. Mors NP; Børglum AD Ugeskr Laeger; 2005 May; 167(20):2191-3. PubMed ID: 15987082 [No Abstract] [Full Text] [Related]
23. Preliminary studies on CSF gamma-aminobutyric acid levels in psychiatric patients before and during treatment with different psychotropic drugs. Zimmer R; Teelken AW; Meier KD; Ackenheil M; Zander KJ Prog Neuropsychopharmacol; 1980; 4(6):613-20. PubMed ID: 7220676 [No Abstract] [Full Text] [Related]
24. The polyamines in the central nervous system. Shaw GG Biochem Pharmacol; 1979; 28(1):1-6. PubMed ID: 31889 [No Abstract] [Full Text] [Related]
25. The role of GABA and related amino acids in some functions of the central nervous system. A review. Tapia R; Massieu GH Bol Estud Med Biol; 1969 Apr; 26(2):53-67. PubMed ID: 4916454 [No Abstract] [Full Text] [Related]
26. Medications in long-term care: when less is more. Meeks TW; Culberson JW; Horton MS Clin Geriatr Med; 2011 May; 27(2):171-91. PubMed ID: 21641504 [TBL] [Abstract][Full Text] [Related]
27. The dopamine D3 receptor: From preclinical studies to the treatment of psychiatric disorders. Drago F Eur Neuropsychopharmacol; 2015 Sep; 25(9):1399-400. PubMed ID: 26278782 [No Abstract] [Full Text] [Related]
28. The use of psychotropic drugs in developing countries. Harding TW; Chrusciel TL Bull World Health Organ; 1975; 52(3):359-67. PubMed ID: 1084806 [TBL] [Abstract][Full Text] [Related]
29. The effects of psychopharmacological agents on central nervous system amine metabolism in man. Maas JW Annu Rev Pharmacol Toxicol; 1977; 17():411-24. PubMed ID: 17358 [No Abstract] [Full Text] [Related]
30. [The future of biological psychiatry]. Linnoila M Duodecim; 1985; 101(17):1732-7. PubMed ID: 2865128 [No Abstract] [Full Text] [Related]
33. Use of psychotropic drugs and associated dental diseases. Fratto G; Manzon L Int J Psychiatry Med; 2014; 48(3):185-97. PubMed ID: 25492713 [TBL] [Abstract][Full Text] [Related]
34. [MANAGEMENT OF PSYCHOTROPIC DRUGS IN HIV-INFECTED PATIENTS]. Zirulnik JL Vertex; 2015; 26(121):217-23. PubMed ID: 26650559 [TBL] [Abstract][Full Text] [Related]
35. Psychotropic medications and the oncology patient. Pies R Cancer Pract; 1996; 4(3):164-6. PubMed ID: 8826146 [No Abstract] [Full Text] [Related]
36. Psychotropic drugs and mental illness. WHO Chron; 1976 Oct; 30(10):420-4. PubMed ID: 969489 [No Abstract] [Full Text] [Related]
37. [Old and new thought concepts on the biochemical principles of psychopharmcotherapy]. Wunderlich H; Wunderlich HP Samml Zwangl Abh Geb Psychiatr Neurol; 1982; 50():61-80. PubMed ID: 6130615 [No Abstract] [Full Text] [Related]
38. Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases? Griebel G; Beeské S Pharmacol Ther; 2012 Jan; 133(1):116-23. PubMed ID: 21963368 [TBL] [Abstract][Full Text] [Related]
39. Geriatric psychopharmacology. Salzman C Annu Rev Med; 1985; 36():217-28. PubMed ID: 2859829 [TBL] [Abstract][Full Text] [Related]
40. Voltage-operated calcium channels: characteristics and their role in the mechanism of action of psychotropic drugs. Antkiewicz-Michaluk L Pol J Pharmacol; 1999; 51(2):179-86. PubMed ID: 10425648 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]